Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG

Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Glutsch, Valerie, Schummer, Patrick, Kneitz, Hermann, Gesierich, Anja, Goebeler, Matthias, Klein, Detlef, Posch, Christian, Gebhardt, Christoffer, Haferkamp, Sebastian, Zimmer, Lisa, Becker, Jürgen C, Leiter, Ulrike, Weichenthal, Michael, Schadendorf, Dirk, Ugurel, Selma, Schilling, Bastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716995/
https://www.ncbi.nlm.nih.gov/pubmed/36450381
http://dx.doi.org/10.1136/jitc-2022-005930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716995/
https://www.ncbi.nlm.nih.gov/pubmed/36450381
http://dx.doi.org/10.1136/jitc-2022-005930

Ejemplares similares